Cartesian Therapeutics, Inc.
RNAC
$10.79
-$0.46-4.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.11% | -81.16% | -109.18% | -94.09% | 537.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.11% | -81.16% | -109.18% | -94.09% | 537.17% |
| Cost of Revenue | 133.25% | 79.07% | -30.43% | -12.32% | -95.64% |
| Gross Profit | -104.63% | -103.41% | -51.08% | -70.72% | 360.66% |
| SG&A Expenses | 3.03% | -6.05% | -56.62% | -0.79% | 15.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.30% | 25.02% | -43.56% | -8.43% | -17.58% |
| Operating Income | -258.54% | -74.44% | 21.26% | -34.52% | 173.81% |
| Income Before Tax | 14.82% | 68.83% | 94.93% | -168.64% | 221.51% |
| Income Tax Expenses | -- | -- | 101.51% | -- | -- |
| Earnings from Continuing Operations | 14.82% | 68.83% | 94.23% | -168.64% | 221.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.82% | 68.83% | 94.23% | -168.64% | 221.51% |
| EBIT | -258.54% | -74.44% | 21.26% | -34.52% | 173.81% |
| EBITDA | -252.10% | -67.67% | 22.39% | -34.27% | 175.58% |
| EPS Basic | -11.36% | 94.01% | 99.01% | 35.44% | 125.86% |
| Normalized Basic EPS | -210.22% | 77.43% | 97.82% | 75.75% | 130.45% |
| EPS Diluted | -7.41% | 94.01% | 98.98% | 35.44% | 124.22% |
| Normalized Diluted EPS | -215.22% | 77.43% | 97.82% | 75.75% | 128.62% |
| Average Basic Shares Outstanding | 55.35% | 378.45% | 380.19% | 316.10% | 226.97% |
| Average Diluted Shares Outstanding | 48.65% | 378.45% | 380.19% | 316.10% | 247.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |